Table 2.

Radiographic and functional progression by length of time being in MDA: mean (standard deviation) (sample size).

Number of times in MDA
01234p
AIM Study
  Core set definition
    Radiographic progression
      Erosion score0.86 (2.45) (n = 413)0.75 (1.51) (n = 80)0.74 (1.31) (n = 45)0.40 (1.44) (n = 37)0.20 (0.94) (n = 40)0.3221
      JSN score0.51 (0.50) (n = 459)0.46 (0.50) (n = 84)0.57 (0.50) (n = 49)0.56 (0.50) (n = 41)0.73 (0.45) (n = 40)0.0748
      Total score1.68 (4.22) (n = 413)1.67 (2.97) (n = 80)1.34 (2.41) (n = 45)0.80 (2.20) (n = 37)0.49 (1.90) (n = 40)0.2571
    Functional progression
      HAQ–0.39 (0.58) (n = 443)–0.79 (0.64) (n = 82)–0.83 (0.63) (n = 48)–1.18 (0.66) (n = 39)–1.17 (0.61) (n = 37)< 0.0001 0 vs 1,2,3,4 1 vs 3,4
  DAS-based definition
    Radiographic progression
      Erosion score0.85 (2.32) (n = 482)0.39 (1.41) (n = 72)0.36 (1.00) (n = 40)0.1136
      JSN score0.51 (0.50) (n = 519)0.64 (0.48) (n = 78)0.50 (0.51) (n = 46)0.0874
      Total score1.71 (4.07) (n = 482)0.79 (2.44) (n = 72)0.78 (1.99) (n = 40)0.0695
    Functional progression
      HAQ–0.47 (0.63) (n = 503)–0.95 (0.55) (n = 75)–1.05 (0.64) (n = 42)< 0.0001 0 vs 1,2
ATTAIN Study
  Core set definition
    Functional progression
      HAQ–0.26 (0.48) (n = 344)–0.96 (0.58) (n = 24)–1.23 (0.67) (n = 13)< 0.0001 0 vs 1,2
  DAS-based definition
    Functional progression
      HAQ–0.29 (0.50) (n = 287)–0.92 (0.72) (n = 28)< 0.0001
  • MDA: minimal disease activity; JSN: joint space narrowing; DAS: disease activity score; HAQ: health assessment questionnaire.